Core Viewpoint - The stock of Pagoda Biopharma-B (02565) has risen over 8%, reaching a new high of 52.2 HKD, driven by positive clinical trial results for PB-718 [1] Group 1: Clinical Trial Results - Pagoda Biopharma disclosed results from an Ib/IIa clinical trial for PB-718, showing a significant reduction in liver fat content (MRI-PDFF) after 18 weeks of treatment at a dosage of 1.6 mg, with a mean percentage change of -57.14% from baseline and a maximum reduction of 62% [1] - In comparison, the previously reported results for semaglutide in the MASH phase II study indicated a 46.2% reduction in liver fat content after 24 weeks at a dosage of 2.4 mg [1] Group 2: Product Pipeline and Strategy - The company has successfully established a pipeline of six investigational drugs targeting chronic diseases, with a core strategy focused on treating metabolic diseases and their complications [1] - Pagoda Biopharma anticipates commercializing PB-119 in China soon, as its New Drug Application (NDA) has been accepted by the National Medical Products Administration [1] - The internal evaluation indicates that several candidate drugs possess dual value potential as both "first-in-class" (FIC) and "best-in-class" (BIC), laying a solid foundation for future market competitiveness [1]
派格生物医药-B涨超8%破顶 PB-718最新临床数据亮眼 PB-119商业化在即